Catalyst Wire Dossier Catalyst Wire Dossier
EMA guidance · 2014-10-24

Scenesse recommended for rare disease that causes intolerance to sunlight

View source ↗

Summary

EMA recommends Scenesse for a rare disease causing intolerance to sunlight, signaling regulatory consideration or support for the drug's use in this condition.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SCENESSE (afamelanotide)